Pharma Mar, S.A.
PHMMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.77 | -0.02 | 0.73 | 0.05 |
| FCF Yield | 1.02% | 0.57% | -0.48% | -0.01% |
| EV / EBITDA | -779.68 | 53.12 | -1,275.35 | 90.04 |
| Quality | ||||
| ROIC | -2.34% | 8.85% | -1.17% | 3.46% |
| Gross Margin | 87.90% | 95.07% | 91.25% | 97.29% |
| Cash Conversion Ratio | -4.07 | 0.39 | 1.61 | 0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.43% | 2.63% | -0.26% | -3.79% |
| Free Cash Flow Growth | 135.22% | 213.85% | -3,195.15% | -137.66% |
| Safety | ||||
| Net Debt / EBITDA | -0.31 | 1.14 | 7.60 | -0.80 |
| Interest Coverage | -52.73 | 30.23 | -3.77 | 1.98 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.06 | 0.07 | 0.03 |
| Cash Conversion Cycle | 296.39 | 497.51 | 310.71 | 903.25 |